FDA Approves Emergency Use Authorization For Gilead’s Remdesivir To Treat Patients With COVID-19; BARDA Researching New Diagnostic Test

STAT: FDA to allow emergency use of Gilead’s Covid-19 drug
“The Food and Drug Administration announced Friday that it would permit emergency use of remdesivir, the antiviral medicine from Gilead Sciences, to treat patients with Covid-19. The decision to issue an ’emergency use authorization’ was based on positive results from a government-conducted clinical trial, announced Wednesday, that showed remdesivir accelerated the recovery time of patients with Covid-19 compared to a placebo and from a study conducted by Gilead that studied two different treatment durations of the medicine…” (Feuerstein/Herper, 5/1).

The Guardian: U.S. germ warfare research leads to new early Covid-19 test (Tremlett, 5/1).

New York Times: How Remdesivir, New Hope for Covid-19 Patients, Was Resurrected (Kolata, 5/1).